The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Sulindac Inhibits Activation of the NF-κB Pathway
Open accessAbstract
Sulindac is a non-steroidal anti-inflammatory agent that is related both structurally and pharmacologically to indomethacin. In addition to its anti-inflammatory properties, sulindac has been demonstrated to have a role in the prevention of colon cancer. Both its growth inhibitory and anti-inflammatory properties are due at least in part to its ability to decrease prostaglandin synthesis by inhibiting the activity of cyclooxygenases. Recently, we demonstrated that both aspirin and sodium salicylate, but not indomethacin, inhibited the activity of an IκB kinase β (IKKβ) that is required to activate the nuclear factor-κB (NF-κB) pathway. In this study, we show that sulindac and its metabolites sulindac sulfide and sulindac sulfone can also inhibit the NF-κB pathway in both colon cancer and other cell lines. Similar to our previous results with aspirin, this inhibition is due to sulindac-mediated decreases in IKKβ kinase activity. Concentrations of sulindac that inhibit IKKβ activity also reduce the proliferation of colon cancer cells. These results suggest that the growth inhibitory and anti-inflammatory properties of sulindac may be regulated in part by inhibition of kinases that regulate the NF-κB pathway. Sulindac is a non-steroidal anti-inflammatory agent that is related both structurally and pharmacologically to indomethacin. In addition to its anti-inflammatory properties, sulindac has been demonstrated to have a role in the prevention of colon cancer. Both its growth inhibitory and anti-inflammatory properties are due at least in part to its ability to decrease prostaglandin synthesis by inhibiting the activity of cyclooxygenases. Recently, we demonstrated that both aspirin and sodium salicylate, but not indomethacin, inhibited the activity of an IκB kinase β (IKKβ) that is required to activate the nuclear factor-κB (NF-κB) pathway. In this study, we show that sulindac and its metabolites sulindac sulfide and sulindac sulfone can also inhibit the NF-κB pathway in both colon cancer and other cell lines. Similar to our previous results with aspirin, this inhibition is due to sulindac-mediated decreases in IKKβ kinase activity. Concentrations of sulindac that inhibit IKKβ activity also reduce the proliferation of colon cancer cells. These results suggest that the growth inhibitory and anti-inflammatory properties of sulindac may be regulated in part by inhibition of kinases that regulate the NF-κB pathway. nuclear factor-κB IκB kinase inhibitor of κB NF-κB inducing kinase mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1 glutathione S-transferase tumor necrosis factor α phosphate-buffered saline stress-activated protein kinase extracellular response kinase 2 human immunodeficiency virus amino acids mitogen-activated protein. The NF-κB1 pathway regulates the cellular response to a variety of stimuli including cytokines, bacterial and viral infection, and activation of cellular stress pathways (reviewed in Refs. 1Baeuerle P.A. Baltimore D. Cell. 1996; 87: 13-20Abstract Full Text Full Text PDF PubMed Scopus (2910) Google Scholar and 2Baldwin A.S. Annu. Rev. Immunol. 1996; 14: 649-681Crossref PubMed Scopus (5515) Google Scholar). The NF-κB pathway is also critical for the control of cellular growth properties (3Lu X. Xie W. Reed D. Bradshaw W.S. Simmons D.L. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 7961-7965Crossref PubMed Scopus (195) Google Scholar, 4Wang C.Y. Mayo M.W. Korneluk R.G. Goeddel D.V. Baldwin Jr., A.S. Science. 1998; 281: 1680-1683Crossref PubMed Scopus (2552) Google Scholar, 5Beg A.A. Sha W.C. Bronson R.T. Ghosh S. Baltimore D. Nature. 1995; 376: 167-170Crossref PubMed Scopus (1620) Google Scholar, 6Chu Z.-L. McKinsey T.A. Liu L. Gentry J.J. Malim M.H. Ballard D.W. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 10057-10062Crossref PubMed Scopus (819) Google Scholar, 7Wu M. Lee H. Bellas R.E. Schauer S.L. Arsura M. Katz D. FitzGerald M.J. Rothstein T.L. Sherr D.H. Sonenshein G.E. EMBO J. 1996; 15: 4682-4690Crossref PubMed Scopus (553) Google Scholar). For example, disruption of the gene encoding the p65 member of the NF-κB family leads to severe hepatic apoptosis indicating that at least in some cell types that NF-κB is a critical anti-apoptotic factor (5Beg A.A. Sha W.C. Bronson R.T. Ghosh S. Baltimore D. Nature. 1995; 376: 167-170Crossref PubMed Scopus (1620) Google Scholar). Inhibition of apoptosis is likely mediated by NF-κB induction of cellular genes such as cellular inhibitor of apoptosis-1 and -2 which inhibit the apoptotic process (4Wang C.Y. Mayo M.W. Korneluk R.G. Goeddel D.V. Baldwin Jr., A.S. Science. 1998; 281: 1680-1683Crossref PubMed Scopus (2552) Google Scholar, 6Chu Z.-L. McKinsey T.A. Liu L. Gentry J.J. Malim M.H. Ballard D.W. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 10057-10062Crossref PubMed Scopus (819) Google Scholar). The fact that high constitutive levels of NF-κB are found in the nucleus of some tumors further implicates activation of this pat
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
THE NF-κB AND IκB PROTEINS: New Discoveries and Insights
Baldwin, A. S. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.649 · Cited by 4,979
Baeuerle, P. A., & Baltimore, D. (1996) · Cell · doi:10.1016/s0092-8674(00)81318-5 · Cited by 3,001
Wang, C.-Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., & Baldwin, A. S. (1998) · Science · doi:10.1126/science.281.5383.1680 · Cited by 2,711
The stress-activated protein kinase subfamily of c-Jun kinases
Kyriakis, J. M., Banerjee, P., Nikolakaki, E., Dai, T., Rubie, E. A., Ahmad, M. F., Avruch, J., & Woodgett, J. R. (1994) · Nature · doi:10.1038/369156a0 · Cited by 2,596
A cytokine-responsive IκB kinase that activates the transcription factor NF-κB
DiDonato, J. A., Hayakawa, M., Rothwarf, D. M., Zandi, E., & Karin, M. (1997) · Nature · doi:10.1038/41493 · Cited by 2,125
IKK-1 and IKK-2: Cytokine-Activated IκB Kinases Essential for NF-κB Activation
Mercurio, F., Zhu, H., Murray, B. W., Shevchenko, A., Bennett, B. L., Li, J. W., Young, D. B., Barbosa, M., Mann, M., Manning, A., et al. (1997) · Science · doi:10.1126/science.278.5339.860 · Cited by 2,040
The pharmacological basis of therapeutics
Starr, I. (1941) · American Heart Journal · doi:10.1016/s0002-8703(41)90958-4 · Cited by 1,902
Boulton, T. G., Nye, S. H., Robbins, D. J., Ip, N. Y., Radzlejewska, E., Morgenbesser, S. D., DePinho, R. A., Panayotatos, N., Cobb, M. H., & Yancopoulos, G. D. (1991) · Cell · doi:10.1016/0092-8674(91)90098-j · Cited by 1,897
Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB
Beg, A. A., Sha, W. C., Bronson, R. T., Ghosh, S., & Baltimore, D. (1995) · Nature · doi:10.1038/376167a0 · Cited by 1,825
Cited by
NF-κB in cancer: from innocent bystander to major culprit
Karin, M., Cao, Y., Greten, F. R., & Li, Z.-W. (2002) · Nature Reviews Cancer · doi:10.1038/nrc780 · Cited by 2,478
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
Terzić, J., Grivennikov, S., Karin, E., & Karin, M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.058 · Cited by 1,974
Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer
Yamamoto, Y., & Gaynor, R. B. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11914 · Cited by 1,585
Self-citationThun, M. J., Henley, S. J., & Patrono, C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.252 · Cited by 1,433
The role of cyclooxygenases in inflammation, cancer, and development
Williams, C. S., Mann, M., & DuBois, R. N. (1999) · Oncogene · doi:10.1038/sj.onc.1203286 · Cited by 1,417
The IKK NF-κB system: a treasure trove for drug development
Karin, M., Yamamoto, Y., & Wang, Q. M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1279 · Cited by 1,364
Self-citationNF-kB in development and progression of human cancer
Dolcet, X., Llobet, D., Pallares, J., & Matias-Guiu, X. (2005) · Virchows Archiv · doi:10.1007/s00428-005-1264-9 · Cited by 1,169
Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2
Gupta, R. A., & DuBois, R. N. (2001) · Nature Reviews Cancer · doi:10.1038/35094017 · Cited by 1,066
Series Introduction: The transcription factor NF-κB and human disease
Baldwin, A. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11891 · Cited by 990
Wang, D. (2006) · Gut · doi:10.1136/gut.2004.047100 · Cited by 899
Role of BAX in the Apoptotic Response to Anticancer Agents
Zhang, L., Yu, J., Park, B. H., Kinzler, K. W., & Vogelstein, B. (2000) · Science · doi:10.1126/science.290.5493.989 · Cited by 863
Inhibiting NF-κB activation by small molecules as a therapeutic strategy
Gupta, S. C., Sundaram, C., Reuter, S., & Aggarwal, B. B. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.05.004 · Cited by 762
Cyclooxygenase‐independent actions of cyclooxygenase inhibitors
Tegeder, I., Pfeilschifter, J., & Geisslinger, G. (2001) · The FASEB Journal · doi:10.1096/fj.01-0390rev · Cited by 747
Nuclear factor-κB inhibitors as sensitizers to anticancer drugs
Nakanishi, C., & Toi, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1588 · Cited by 724
Kwok, B. H. B., Koh, B., Ndubuisi, M. I., Elofsson, M., & Crews, C. M. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00049-7 · Cited by 515
Nuclear factor-kappa B and cancer: its role in prevention and therapy
Bharti, A. C., & Aggarwal, B. B. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01154-1 · Cited by 510
Chemoprevention of Colorectal Cancer
Jänne, P. A., & Mayer, R. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422606 · Cited by 496
At the Crossroads of Inflammation and Cancer
Clevers, H. (2004) · Cell · doi:10.1016/j.cell.2004.09.005 · Cited by 493
Long-term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs and Risk of Colorectal Cancer
Chan, A. T. (2005) · JAMA · doi:10.1001/jama.294.8.914 · Cited by 478
Many actions of cyclooxygenase‐2 in cellular dynamics and in cancer
Cao, Y., & Prescott, S. M. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10068 · Cited by 464
Roninson, I. B. (2002) · Cancer Letters · doi:10.1016/s0304-3835(01)00847-3 · Cited by 443
17β-Estradiol Inhibits Inflammatory Gene Expression by Controlling NF-κB Intracellular Localization
Ghisletti, S., Meda, C., Maggi, A., & Vegeto, E. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.8.2957-2968.2005 · Cited by 430
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Xu, Y., & Villalona-Calero, M. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf337 · Cited by 413
The IKK/NF-κB activation pathway—a target for prevention and treatment of cancer
Greten, F. (2004) · Cancer Letters · doi:10.1016/j.canlet.2003.08.029 · Cited by 410
Current insights into the regulation of programmed cell death by NF-κB
Dutta, J., Fan, Y., Gupta, N., Fan, G., & Gélinas, C. (2006) · Oncogene · doi:10.1038/sj.onc.1209938 · Cited by 407
Li, F., & Sethi, G. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.01.002 · Cited by 398
Hyperglycemia increases mitochondrial superoxide in retina and retinal cells
Du, Y., Miller, C. M., & Kern, T. S. (2003) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2003.08.018 · Cited by 355
Molecular Pathways: Adipose Inflammation as a Mediator of Obesity-Associated Cancer
Howe, L. R., Subbaramaiah, K., Hudis, C. A., & Dannenberg, A. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2603 · Cited by 344
The role of NF-κB in the regulation of cell stress responses
Wang, T., Zhang, X., & Li, J. J. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00058-9 · Cited by 343
Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?
Gasparini, G., Longo, R., Sarmiento, R., & Morabito, A. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01220-8 · Cited by 330
The transcription factor NF-κB: control of oncogenesis and cancer therapy resistance
Mayo, M. W., & Baldwin, A. S. (2000) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(00)00002-0 · Cited by 324
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
Howe, L. R., Subbaramaiah, K., Brown, A. M., & Dannenberg, A. J. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080097 · Cited by 322
Takada, Y., Bhardwaj, A., Potdar, P., & Aggarwal, B. B. (2004) · Oncogene · doi:10.1038/sj.onc.1208169 · Cited by 310
Lee, J.-H., Koo, T. H., Yoon, H., Jung, H. S., Jin, H. Z., Lee, K., Hong, Y.-S., & Lee, J. J. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.08.014 · Cited by 308
The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients
Hariharan, A., Hakeem, A. R., Radhakrishnan, S., Reddy, M. S., & Rela, M. (2021) · Inflammopharmacology · doi:10.1007/s10787-020-00773-9 · Cited by 295
Nuclear Factor-κB in Development, Prevention, and Therapy of Cancer
Van Waes, C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2221 · Cited by 292
Targeting the NFκB Signaling Pathways for Breast Cancer Prevention and Therapy
Wang, W., Nag, S., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106124315 · Cited by 282
Dormond, O., Foletti, A., Paroz, C., & Rüegg, C. (2001) · Nature Medicine · doi:10.1038/nm0901-1041 · Cited by 281
Weggen, S., Eriksen, J. L., Sagi, S. A., Pietrzik, C. U., Ozols, V., Fauq, A., Golde, T. E., & Koo, E. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303592200 · Cited by 280
The growing challenge of obesity and cancer: an inflammatory issue
Harvey, A. E., Lashinger, L. M., & Hursting, S. D. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06096.x · Cited by 272
IκB kinase β (IKKβ/IKK2/IKBKB)—A key molecule in signaling to the transcription factor NF-κB
Schmid, J. A., & Birbach, A. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.01.006 · Cited by 262
Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention
Chan, T. A. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00680-0 · Cited by 255
Protein phosphatase 2A interacts with and directly dephosphorylates RelA
Yang, J., Fan, G.-H., Wadzinski, B. E., Sakurai, H., & Richmond, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106103200 · Cited by 130
The role of NF-κB/IκB proteins in cancer: implications for novel treatment strategies
Schwartz, S. A., Hernandez, A., & Mark Evers, B. (1999) · Surgical Oncology · doi:10.1016/s0960-7404(00)00012-8 · Cited by 132
Unique MAP Kinase binding sites
Akella, R., Moon, T. M., & Goldsmith, E. J. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.09.016 · Cited by 108
Relevance of new drug discovery to reduce NF-κB activation in cardiovascular disease
Madonna, R., & De Caterina, R. (2012) · Vascular Pharmacology · doi:10.1016/j.vph.2012.02.005 · Cited by 46
Chung, K.-S., Choi, H.-E., Shin, J.-S., Cho, E.-J., Cho, Y.-W., Choi, J.-H., Baek, N.-I., & Lee, K.-T. (2015) · Food and Chemical Toxicology · doi:10.1016/j.fct.2014.11.007 · Cited by 14
Metadata
- Authors
- Yamamoto, Y., Yin, M.-J., Lin, K.-M., & Gaynor, R. B.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1999-09
- Volume
- 274
- Issue
- 38
- Pages
- 27307-27314
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2038554369
- Cited by
- 494
- References
- 54
- FWCI
- 11.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.